共 50 条
Determinants of morbidities and mortality in acromegaly
被引:40
作者:
Kasuki, Leandro
[1
,2
,3
,4
]
Rocha, Paula da Silva
[1
,2
]
Lamback, Elisa Baranski
[1
,2
]
Gadelha, Monica Roberto
[1
,2
,3
,5
]
机构:
[1] Univ Fed Rio de Janeiro, Fac Med, Ctr Pesquisa Neuroendocrinol, Div Endocrinol, Rio De Janeiro, RJ, Brazil
[2] Univ Fed Rio de Janeiro, Hosp Univ Clementino Frage Filho, Rio De Janeiro, RJ, Brazil
[3] Inst Estadual Cerebro Paulo Niemeyer, Serv Neuroendocrinol, Rio De Janeiro, RJ, Brazil
[4] Hosp Fed Bonsucesso Rio de Janeiro, Serv Endocrinol, Rio De Janeiro, RJ, Brazil
[5] Inst Estadual Cerebro Paulo Niemeyer, Lab Neuropatol & Genet Mol, Rio De Janeiro, RJ, Brazil
来源:
ARCHIVES OF ENDOCRINOLOGY METABOLISM
|
2019年
/
63卷
/
06期
关键词:
Acromegaly;
systemic complications;
mortality;
cardiovascular disease;
cancer;
GROWTH-FACTOR-I;
IGF-I;
VERTEBRAL FRACTURES;
DIABETES-MELLITUS;
HIGH PREVALENCE;
BONE TURNOVER;
LOW-FREQUENCY;
RISK;
CANCER;
COMORBIDITIES;
D O I:
10.20945/2359-3997000000193
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Acromegaly is a systemic disease associated with increased morbidity, presenting cardiovascular, metabolic, respiratory, neoplastic, endocrine, articular and bone complications. Most of these comorbidities can be prevented or delayed with adequate disease treatment and, more recent studies with the use of modern treatments of acromegaly, have shown a change in the severity and prevalence of these complications. In addition, acromegaly is associated with increased mortality, but recent studies (especially those published in the last decade) have shown a different scenario than older studies, with mortality no longer being increased in adequately controlled patients and a change in the main cause of death from cardiovascular disease to malignancy. In this review, we discuss this changing face of acromegaly summarizing current knowledge and evidence on morbimortality of the disease.
引用
收藏
页码:630 / 637
页数:8
相关论文